State Street Corp Impel Pharmaceuticals Inc Transaction History

State Street Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.96 - $4.1 $11,808 - $50,429	-12,300 Reduced 32.8%	25,200 $35,000
Q4 2022 Feb 14, 2023	SELL	$2.59 - $4.0 $10,878 - $16,800	-4,200 Reduced 10.07%	37,500 $140,000
Q2 2022 Aug 15, 2022	SELL	$5.83 - $10.12 $806,551 - $1.4 Million	-138,345 Reduced 76.84%	41,700 $389,000
Q1 2022 May 16, 2022	BUY	$5.86 - $9.85 $65,087 - $109,403	11,107 Added 6.57%	180,045 $1.15 Million
Q4 2021 Feb 14, 2022	BUY	$8.33 - $12.14 $332,900 - $485,162	39,964 Added 30.99%	168,938 $1.46 Million
Q3 2021 Nov 15, 2021	BUY	$8.38 - $26.13 $692,824 - $2.16 Million	82,676 Added 178.57%	128,974 $1.57 Million
Q2 2021 Aug 16, 2021	BUY	$7.33 - $15.2 $339,364 - $703,729	46,298 New	46,298 $410,000

14.4K

Ticker IMPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 23,738,800
Market Cap $475K
Description
Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The c...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.